Heiden seeks: The new AMAG CEO outlines a strategy of cost-reduction and acquisition
This article was originally published in Scrip
William Heiden joined AMAG Pharmaceuticals as president and CEO in May 2012, at a time when the public company was struggling to find its way forward. Since then he's been paving a path toward profitability.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.